Driven by evidence
Treat complex aneurysms with
Contour Neurovascular System™
With 6 key clinical studies and counting, the Contour Neurovascular System is proven to be effective in the treatment of aneurysms.
"The findings demonstrate that the Contour Neurovascular System is a promising technology for the endovascular embolization of cerebral aneurysms.
With its high occlusion rates and safety profile, Contour could be considered a viable alternative to existing intrasaccular devices."
Contour Neurovascular System for endovascular embolization of cerebral aneurysms: a multicenter cohort study of 10 European neurovascular centers
___________
Method:
Retrospective review of utilizing prospectively collected cases from 10 European neurovascular centers, gathered between February 2017 and October 2022.
British Medical Journal (BMJ) | 2024
Christoph J Griessenauer | Sherief Ghozy | Alessandra Biondi | Constantin Hecker | Fritz Wodarg | Thomas Liebig | Tufail Patankar | Saleh Lamin | Mario Martínez-Galdámez | Christophe Cognard | Jens Fiehler | Franziska Dorn | Adam A Dmytriw | Monika Killer-Oberpfalzer
Results
Efficacy:
91.5%
91.5%
Adequate occlusion rate
At 6-12 month follow-up:
• Functional outcomes
- mRS 0 or 1 in 92.5%
Retreatment rate:
2.5%
2.5%
Retreatment rate
No association between rupture status or aneurysm size on occlusion rates or complications
Ease of use:
2.9%
2.9%
Change in size
Size simplified
•95.3% technical success
Safety:
0.4%
0.4%
HEM complication rate
•6.8% thromboembolic complications
•0.0% procedure-related mortality*
Overview
279 aneurysms
Median age 60 years, IQR 52-68 years
Aneurysm location
MCA 74 (26.5%)
ACOM 73 (26.2%)
Basilar tip 65 (23.3%)
ICA terminus/bifurcation 27 (9.7%)
ICA sidewall 15 (5.4%)
PCOM 16 (5.7%)
Other 9 (3.3%)
Median aneurysm size:
| Dome | 5.2mm (IQR 4.2-7.0) |
| Height | 5.7mm (IQR 4.3-7.8) |
| Neck | 3.9mm (IQR 3.0-5.0) |
- 83.2% elective, (16.8% ruptured) 11.1% acute SAH, 5.7% prior SAH.
- Reflects real-world usage, including atypical aneurysm locations (sidewall, non-bifurcation).
- Dual antiplatelets were given in 46.6% of aneurysms, monotherapy in 49.1%, and no antiplatelets were given in 4.3%.
We are driven by clinical evidence and committed to proving the safety and effectiveness of our products in treating the toughest stroke cases.
Contact us.
Thank you for your submission.
*There were four mortalities reported each at discharge and last follow-up, respectively, neither related to the Contour procedure.
This document is intended solely for the use of healthcare professionals.
A physician must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that physicians be trained in the use of any particular product before using it in a procedure. The information presented is intended to demonstrate the breadth of Stryker product offerings. A physician must always refer to the package insert, product label and/or instructions for use before using any Stryker product.
Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Stryker representative if you have questions about the availability of Stryker products in your area.
Stryker or its affiliated entities own, use, or have applied for the following trademarks or service marks: Contour Neurovascular System, Stryker. All other trademarks are trademarks of their respective owners or holders.
The absence of a product, feature, or service name, or logo from this list does not constitute a waiver of Stryker’s trademark or other intellectual property rights concerning that name or logo.
AP004642 v1.0